Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 71 | BES2020 | Next issue

Belgian Endocrine Society 2020

Online, Online
11 Nov 2020 - 11 Nov 2020

Card image cap

BES 2020

Bone impact of long-term replacement therapy with recombinant human parathyroid hormone (1-34) in adult patients with hypoparathyroidism evaluated by bone scintigraphy

ea0071013 | Bone impact of long-term replacement therapy with recombinant human parathyroid hormone (1-34) in adult patients with hypoparathyroidism evaluated by bone scintigraphy | BES2020

Bone impact of long-term replacement therapy with recombinant human parathyroid hormone (1–34) in adult patients with hypoparathyroidism evaluated by bone scintigraphy

R Fischler , AL Lecoq , F Besson , K Briot , S Salenave , C Goujart , S Leboulleux , E Carreira , L Bricaire , C Chabrolle , B Corvilain , C Philippe , A Linglart , G Grimon , P Kamenicky

Introduction: Recombinant human parathyroid hormone (rPTH) (1–34) is prescribed off-label in France for patients with hypoparathyroidism resistant to conventional therapy. However, the bone impact of this long-term replacement therapy is not well known.Objective: To determine the skeletal impact of chronic treatment with rPTH (1–34) in patients with hypoparathyroidism.Design: Single-center prospective study. Patients trea...